Boys Arnold & Co. Inc. trimmed its stake in shares of Merck & Company, Inc. (NYSE:MRK) by 1.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 60,970 shares of the company’s stock after selling 1,210 shares during the quarter. Boys Arnold & Co. Inc.’s holdings in Merck & were worth $3,908,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. RB Capital Management LLC lifted its holdings in Merck & by 0.5% in the 2nd quarter. RB Capital Management LLC now owns 4,587 shares of the company’s stock worth $294,000 after buying an additional 23 shares during the period. Baystate Wealth Management LLC lifted its holdings in Merck & by 0.4% in the 2nd quarter. Baystate Wealth Management LLC now owns 6,470 shares of the company’s stock worth $405,000 after buying an additional 27 shares during the period. Bath Savings Trust Co lifted its holdings in Merck & by 0.5% in the 2nd quarter. Bath Savings Trust Co now owns 5,427 shares of the company’s stock worth $348,000 after buying an additional 28 shares during the period. Camelot Portfolios LLC lifted its holdings in Merck & by 0.4% in the 1st quarter. Camelot Portfolios LLC now owns 7,771 shares of the company’s stock worth $494,000 after buying an additional 33 shares during the period. Finally, Stillwater Investment Management LLC lifted its holdings in Merck & by 0.8% in the 2nd quarter. Stillwater Investment Management LLC now owns 4,621 shares of the company’s stock worth $296,000 after buying an additional 38 shares during the period. Institutional investors and hedge funds own 73.15% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Boys Arnold & Co. Inc. Sells 1,210 Shares of Merck & Company, Inc. (MRK)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.thecerbatgem.com/2017/11/18/boys-arnold-co-inc-sells-1210-shares-of-merck-company-inc-mrk.html.

Merck & Company, Inc. (MRK) opened at $55.20 on Friday. Merck & Company, Inc. has a 52-week low of $54.40 and a 52-week high of $66.80. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.16 and a current ratio of 1.43. The firm has a market capitalization of $150,470.00, a P/E ratio of 14.14, a P/E/G ratio of 2.37 and a beta of 0.78.

Merck & (NYSE:MRK) last posted its quarterly earnings data on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.08. Merck & had a return on equity of 27.08% and a net margin of 11.60%. The company had revenue of $10.33 billion during the quarter, compared to analyst estimates of $10.54 billion. During the same quarter last year, the company earned $1.07 EPS. The firm’s revenue for the quarter was down 2.0% on a year-over-year basis. equities analysts forecast that Merck & Company, Inc. will post 3.95 earnings per share for the current year.

Several research firms have weighed in on MRK. J P Morgan Chase & Co set a $70.00 price objective on Merck & and gave the stock a “buy” rating in a report on Sunday, October 29th. Berenberg Bank reiterated a “hold” rating on shares of Merck & in a report on Wednesday, November 1st. Sanford C. Bernstein reiterated a “buy” rating and issued a $64.00 price objective on shares of Merck & in a report on Wednesday. BMO Capital Markets set a $70.00 price objective on Merck & and gave the stock a “buy” rating in a report on Wednesday, October 18th. Finally, Zacks Investment Research cut Merck & from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have issued a buy rating to the company’s stock. Merck & presently has a consensus rating of “Hold” and an average target price of $66.87.

In related news, Director Thomas H. Glocer sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total transaction of $281,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.25% of the stock is owned by company insiders.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Stock Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related stocks with our FREE daily email newsletter.